journal
https://read.qxmd.com/read/36898397/on-the-occasion-of-international-women-s-day
#1
LETTER
R M Anjana
No abstract text is available yet for this article.
March 7, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36878241/the-growing-clinical-effect-of-sglt2-inhibitors
#2
JOURNAL ARTICLE
Stefano Del Prato
No abstract text is available yet for this article.
March 3, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36878240/let-s-talk-about-obesity
#3
EDITORIAL
The Lancet Diabetes Endocrinology
No abstract text is available yet for this article.
March 3, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36878239/effects-of-dapagliflozin-on-hospitalisations-in-people-with-type-2-diabetes-post-hoc-analyses-of-the-declare-timi-58-trial
#4
JOURNAL ARTICLE
Meir Schechter, Stephen D Wiviott, Itamar Raz, Erica L Goodrich, Aliza Rozenberg, Ilan Yanuv, Sabina A Murphy, Thomas A Zelniker, Martin Fredriksson, Peter A Johansson, Lawrence A Leiter, Deepak L Bhatt, Darren K McGuire, John P H Wilding, Ingrid A M Gause-Nilsson, Avivit Cahn, Anna Maria Langkilde, Marc S Sabatine, Ofri Mosenzon
BACKGROUND: In people with type 2 diabetes at high risk of cardiovascular or kidney disease, sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of hospitalisations for heart failure. Less is known about their effects on hospitalisation from any cause, especially in people with type 2 diabetes without atherosclerotic cardiovascular disease, which includes most of the global population of people with type 2 diabetes. We aimed to assess the effect of the SGLT2 inhibitor, dapagliflozin, on the risks of hospitalisations for any cause and for specific causes in people with type 2 diabetes with and without atherosclerotic cardiovascular disease...
March 3, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36878238/lancet-diabetes-endocrinology-commission-on-the-definition-and-diagnosis-of-clinical-obesity
#5
JOURNAL ARTICLE
Francesco Rubino, Rachel L Batterham, Marta Koch, Geltrude Mingrone, Carel W le Roux, I Sadaf Farooqi, Nathalie Farpour-Lambert, Edward W Gregg, David E Cummings
No abstract text is available yet for this article.
March 3, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36871565/rossella-nappi-taking-the-stigma-out-of-menopause
#6
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
March 2, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36868256/trends-in-incidence-of-youth-onset-type-1-and-type-2-diabetes-in-the-usa-2002-18-results-from-the-population-based-search-for-diabetes-in-youth-study
#7
JOURNAL ARTICLE
Lynne E Wagenknecht, Jean M Lawrence, Scott Isom, Elizabeth T Jensen, Dana Dabelea, Angela D Liese, Lawrence M Dolan, Amy S Shah, Anna Bellatorre, Katherine Sauder, Santica Marcovina, Kristi Reynolds, Catherine Pihoker, Giuseppina Imperatore, Jasmin Divers
BACKGROUND: The incidence of diabetes is increasing in children and young people. We aimed to describe the incidence of type 1 and type 2 diabetes in children and young people aged younger than 20 years over a 17-year period. METHODS: The SEARCH for Diabetes in Youth study identified children and young people aged 0-19 years with a physician diagnosis of type 1 or type 2 diabetes at five centres in the USA between 2002 and 2018. Eligible participants included non-military and non-institutionalised individuals who resided in one of the study areas at the time of diagnosis...
February 28, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36868255/searching-for-answers-to-youth-onset-type-2-diabetes
#8
JOURNAL ARTICLE
Jonathan E Shaw, Dianna J Magliano
No abstract text is available yet for this article.
February 28, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36848916/hyperthyroidism-aetiology-pathogenesis-diagnosis-management-complications-and-prognosis
#9
REVIEW
Wilmar M Wiersinga, Kris G Poppe, Grigoris Effraimidis
Hyperthyroidism is a common condition with a global prevalence of 0·2-1·3%. When clinical suspicion of hyperthyroidism arises, it should be confirmed by biochemical tests (eg, low TSH, high free thyroxine [FT4 ], or high free tri-iodothyonine [FT3 ]). If hyperthyroidism is confirmed by biochemical tests, a nosological diagnosis should be done to find out which disease is causing the hyperthyroidism. Helpful tools are TSH-receptor antibodies, thyroid peroxidase antibodies, thyroid ultrasonography, and scintigraphy...
February 24, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36848915/mechanisms-of-ageing-growth-hormone-dietary-restriction-and-metformin
#10
REVIEW
Jansher Khan, Ida Pernicova, Kiran Nisar, Márta Korbonits
Tackling the mechanisms underlying ageing is desirable to help to extend the duration and improve the quality of life. Life extension has been achieved in animal models by suppressing the growth hormone-insulin-like growth factor 1 (IGF-1) axis and also via dietary restriction. Metformin has become the focus of increased interest as a possible anti-ageing drug. There is some overlap in the postulated mechanisms of how these three approaches could produce anti-ageing effects, with convergence on common downstream pathways...
February 24, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36803366/current-diagnostic-criteria-identify-risk-for-type-2-diabetes-too-late
#11
JOURNAL ARTICLE
Michael Bergman, Martin Buysschaert, Antonio Ceriello, Akhtar Hussain, Viswanathan Mohan, Giorgio Sesti, Jaakko Tuomilehto
No abstract text is available yet for this article.
February 16, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36758574/the-double-burden-of-poor-diets
#12
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
February 6, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36758573/making-sense-of-weekly-insulins
#13
JOURNAL ARTICLE
Philip Home
No abstract text is available yet for this article.
February 6, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36758572/safety-and-efficacy-of-once-weekly-basal-insulin-fc-in-people-with-type-2-diabetes-previously-treated-with-basal-insulin-a-multicentre-open-label-randomised-phase-2-study
#14
JOURNAL ARTICLE
Juan Frias, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Kristen Syring, Paula Wullenweber, Axel Haupt, Christof Kazda
BACKGROUND: The burden of daily basal insulins often causes hesitancy and delays in the initiation of insulin therapy. Basal insulin Fc (BIF, insulin efsitora alfa), designed for once-weekly administration, is a fusion protein combining a novel single-chain insulin variant with a human immunoglobulin G (IgG) Fc domain. In this study, we explored the safety and efficacy of BIF in people with type 2 diabetes who had been previously treated with basal insulin. METHODS: For this phase 2, 44-site (clinical research centres and hospitals), randomised, open-label, comparator-controlled, 32-week study in the USA, Puerto Rico, and Mexico, we enrolled participants with type 2 diabetes...
February 6, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36746161/a-framework-for-improving-diabetes-care-in-humanitarian-emergencies
#15
JOURNAL ARTICLE
Sylvia Kehlenbrink, Kiran Jobanputra
No abstract text is available yet for this article.
February 3, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36746160/outcomes-in-children-of-women-with-type-2-diabetes-exposed-to-metformin-versus-placebo-during-pregnancy-mity-kids-a-24-month-follow-up-of-the-mity-randomised-controlled-trial
#16
JOURNAL ARTICLE
Denice S Feig, J Johanna Sanchez, Kellie E Murphy, Elizabeth Asztalos, Bernard Zinman, David Simmons, Andrea M Haqq, I George Fantus, Lorraine Lipscombe, Anthony Armson, Jon Barrett, Lois Donovan, Paul Karanicolas, Siobhan Tobin, Kathryn Mangoff, Gail Klein, Yidi Jiang, George Tomlinson, Jill Hamilton
BACKGROUND: Metformin is increasingly being used during pregnancy, with potentially adverse long-term effects on children. We aimed to examine adiposity in children of women with type 2 diabetes from the Metformin in Women with Type 2 Diabetes in Pregnancy (MiTy) trial, with and without in-utero exposure to metformin, up to 24 months of age. METHODS: MiTy Kids is a follow-up study that included infants of women who participated in the MiTy randomised controlled trial, receiving either oral 1000 mg metformin twice daily or placebo...
February 3, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36739873/implications-of-technology-guidelines-for-low-income-and-middle-income-countries
#17
LETTER
Yashdeep Gupta, Alpesh Goyal, Nikhil Tandon
No abstract text is available yet for this article.
February 2, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36738753/a-plan-to-improve-global-type-1-diabetes-epidemiology-data
#18
LETTER
David Beran, Kurt Højlund, Stéphane Besançon, Mads Loftager Mundt, Graham D Ogle, Kaushik Ramaiya, Tom Robinson, Jannet Svensson, Jaakko Tuomilehto, Sarah Wild, Anders Green
No abstract text is available yet for this article.
February 1, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36738752/challenges-in-the-treatment-of-young-people-with-type-2-diabetes
#19
JOURNAL ARTICLE
Sten Madsbad
No abstract text is available yet for this article.
February 1, 2023: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/36738751/efficacy-and-safety-of-the-sglt2-inhibitor-empagliflozin-versus-placebo-and-the-dpp-4-inhibitor-linagliptin-versus-placebo-in-young-people-with-type-2-diabetes-dinamo-a-multicentre-randomised-double-blind-parallel-group-phase-3-trial
#20
JOURNAL ARTICLE
Lori M Laffel, Thomas Danne, Georgeanna J Klingensmith, William V Tamborlane, Steven Willi, Philip Zeitler, Dietmar Neubacher, Jan Marquard
BACKGROUND: The incidence of type 2 diabetes in young people is increasing, but treatments remain limited. We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycaemic control in young people with type 2 diabetes. METHODS: In this double-blind, placebo-controlled trial done in 108 centres in 15 countries, participants with type 2 diabetes (aged 10-17 years; HbA1c 6·5-10·5% [48-91 mmol/mol]) who had been previously treated with metformin or insulin were randomly assigned (1:1:1) to oral empagliflozin 10 mg, oral linagliptin 5 mg, or placebo...
February 1, 2023: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.